Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC)

Abstract

7329 Background: To evaluate efficacy and safety of combination of Gemcitabine plus Cisplatin(GP regimen) and combination of Gemcitabine plus Vinorelbine(GN regimen) in the treatment of advanced non-small cell lung cancer in Chinese patients. Methods: Eighty-two patients with stage III or IV NSCLC were enrolled, 42 patients randomized into GP group and other 40 patients into GN group. Gemcitabine 1000 mg/m2 d1, d8, Cisplatin 80mg/m2 d1 were administered to patients in GP group, while Gemcitabine 1000 mg/m2 d1, d8, Vinorelbine 25mg/m2 d1, d8 were given to patients in GN group, both of these two regimen were repeated every 3 weeks, no more than 6 cycles for each patient. Results: The median survival time (MST) was 9.8 months for GN arm and 8.8 months for GP arm. An objective response rate of 28.6% was observed in GP arm versus 25% in GN arm, 1-year survival rate was 64% in GP arm and 66% in GN arm with no significant difference in statistical analysis (Figure 1). Nausea and vomiting were the major dose-limiting toxicity. The incidence of leukopenia was similar between two groups (p=0.135). The incidence of grade III/IV nausea and vomiting were significantly higher in the GP arm than in the GN arm (Table 1, p=0.0005). Conclusions: Both of GP regimen and GN regimen were effective regimens when used in Chinese advanced NSCLC patients, however in GN regimen the grade III/IV nausea and vomiting was significant lower than that of platinum chemotherapy. No significant financial relationships to disclose.